306 related articles for article (PubMed ID: 21278235)
1. Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells.
Liu YY; Patwardhan GA; Bhinge K; Gupta V; Gu X; Jazwinski SM
Cancer Res; 2011 Mar; 71(6):2276-85. PubMed ID: 21278235
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
[TBL] [Abstract][Full Text] [Related]
3. Direct quantitative determination of ceramide glycosylation in vivo: a new approach to evaluate cellular enzyme activity of glucosylceramide synthase.
Gupta V; Patwardhan GA; Zhang QJ; Cabot MC; Jazwinski SM; Liu YY
J Lipid Res; 2010 Apr; 51(4):866-74. PubMed ID: 19826105
[TBL] [Abstract][Full Text] [Related]
4. Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance.
Liu YY; Hill RA; Li YT
Adv Cancer Res; 2013; 117():59-89. PubMed ID: 23290777
[TBL] [Abstract][Full Text] [Related]
5. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
[TBL] [Abstract][Full Text] [Related]
6. Resuscitating wild-type p53 expression by disrupting ceramide glycosylation: a novel approach to target mutant p53 tumors.
Liu YY
Cancer Res; 2011 Oct; 71(20):6295-9. PubMed ID: 21972148
[TBL] [Abstract][Full Text] [Related]
7. Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma.
Stefanovic M; Tutusaus A; Martinez-Nieto GA; Bárcena C; de Gregorio E; Moutinho C; Barbero-Camps E; Villanueva A; Colell A; Marí M; García-Ruiz C; Fernandez-Checa JC; Morales A
Oncotarget; 2016 Feb; 7(7):8253-67. PubMed ID: 26811497
[TBL] [Abstract][Full Text] [Related]
8. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
[TBL] [Abstract][Full Text] [Related]
9. Folate stress induces apoptosis via p53-dependent de novo ceramide synthesis and up-regulation of ceramide synthase 6.
Hoeferlin LA; Fekry B; Ogretmen B; Krupenko SA; Krupenko NI
J Biol Chem; 2013 May; 288(18):12880-90. PubMed ID: 23519469
[TBL] [Abstract][Full Text] [Related]
10. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
11. p53-Dependent p21-mediated growth arrest pre-empts and protects HCT116 cells from PUMA-mediated apoptosis induced by EGCG.
Thakur VS; Ruhul Amin AR; Paul RK; Gupta K; Hastak K; Agarwal MK; Jackson MW; Wald DN; Mukhtar H; Agarwal ML
Cancer Lett; 2010 Oct; 296(2):225-32. PubMed ID: 20444544
[TBL] [Abstract][Full Text] [Related]
12. p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa.
Valente LJ; Gray DH; Michalak EM; Pinon-Hofbauer J; Egle A; Scott CL; Janic A; Strasser A
Cell Rep; 2013 May; 3(5):1339-45. PubMed ID: 23665218
[TBL] [Abstract][Full Text] [Related]
13. Both p53-PUMA/NOXA-Bax-mitochondrion and p53-p21cip1 pathways are involved in the CDglyTK-mediated tumor cell suppression.
Yu Z; Wang H; Zhang L; Tang A; Zhai Q; Wen J; Yao L; Li P
Biochem Biophys Res Commun; 2009 Sep; 386(4):607-11. PubMed ID: 19540190
[TBL] [Abstract][Full Text] [Related]
14. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
Fraser M; Bai T; Tsang BK
Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
[TBL] [Abstract][Full Text] [Related]
15. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
Wang H; Nan L; Yu D; Agrawal S; Zhang R
Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
[TBL] [Abstract][Full Text] [Related]
16. Activation of p53-dependent apoptosis by acute ablation of glycogen synthase kinase-3beta in colorectal cancer cells.
Ghosh JC; Altieri DC
Clin Cancer Res; 2005 Jun; 11(12):4580-8. PubMed ID: 15958644
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175.
Hayward RL; Schornagel QC; Tente R; Macpherson JS; Aird RE; Guichard S; Habtemariam A; Sadler P; Jodrell DI
Cancer Chemother Pharmacol; 2005 Jun; 55(6):577-83. PubMed ID: 15726367
[TBL] [Abstract][Full Text] [Related]
18. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity.
Piovesan B; Pennell N; Berinstein NL
Oncogene; 1998 Nov; 17(18):2339-50. PubMed ID: 9811465
[TBL] [Abstract][Full Text] [Related]
19. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein.
Takimoto R; Wang W; Dicker DT; Rastinejad F; Lyssikatos J; el-Deiry WS
Cancer Biol Ther; 2002; 1(1):47-55. PubMed ID: 12174820
[TBL] [Abstract][Full Text] [Related]
20. A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells.
Idogawa M; Sasaki Y; Suzuki H; Mita H; Imai K; Shinomura Y; Tokino T
Clin Cancer Res; 2009 Jun; 15(11):3725-32. PubMed ID: 19458054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]